Gilead’s CAR T-Cell Therapy Administered to Just Five Patients in Two Months – The Scientist
The Scientist |
Gilead's CAR T-Cell Therapy Administered to Just Five Patients in Two Months
The Scientist Originally developed by Kite Pharma—a California-based startup that was bought by Gilead for nearly $12 billion in cash earlier this year—Yescarta is just the second CAR T-cell therapy to be approved in the U.S. Doctors at the 15 cancer hospitals … |
